Logo image of ADXN

ADDEX THERAPEUTICS LTD (ADXN) Stock Fundamental Analysis

NASDAQ:ADXN - Nasdaq - US00654J2069 - ADR - Currency: USD

7.6  -0.04 (-0.46%)

Fundamental Rating

3

Overall ADXN gets a fundamental rating of 3 out of 10. We evaluated ADXN against 198 industry peers in the Pharmaceuticals industry. ADXN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ADXN is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ADXN had positive earnings in the past year.
In the past year ADXN has reported a negative cash flow from operations.
ADXN had negative earnings in each of the past 5 years.
ADXN had a negative operating cash flow in each of the past 5 years.
ADXN Yearly Net Income VS EBIT VS OCF VS FCFADXN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M -20M

1.2 Ratios

With an excellent Return On Assets value of 44.42%, ADXN belongs to the best of the industry, outperforming 99.49% of the companies in the same industry.
ADXN's Return On Equity of 48.86% is amongst the best of the industry. ADXN outperforms 97.47% of its industry peers.
Industry RankSector Rank
ROA 44.42%
ROE 48.86%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADXN Yearly ROA, ROE, ROICADXN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K

1.3 Margins

ADXN has a better Profit Margin (912.34%) than 100.00% of its industry peers.
ADXN does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 912.34%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADXN Yearly Profit, Operating, Gross MarginsADXN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K

More info and screens

4

2. Health

2.1 Basic Checks

ADXN does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADXN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ADXN Yearly Shares OutstandingADXN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 100K 200K 300K 400K
ADXN Yearly Total Debt VS Total AssetsADXN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -34.39, we must say that ADXN is in the distress zone and has some risk of bankruptcy.
ADXN's Altman-Z score of -34.39 is on the low side compared to the rest of the industry. ADXN is outperformed by 88.89% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ADXN is not too dependend on debt financing.
The Debt to Equity ratio of ADXN (0.00) is better than 61.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.39
ROIC/WACCN/A
WACC5.15%
ADXN Yearly LT Debt VS Equity VS FCFADXN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 4.59 indicates that ADXN has no problem at all paying its short term obligations.
The Current ratio of ADXN (4.59) is better than 69.70% of its industry peers.
ADXN has a Quick Ratio of 4.59. This indicates that ADXN is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 4.59, ADXN is doing good in the industry, outperforming 71.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.59
Quick Ratio 4.59
ADXN Yearly Current Assets VS Current LiabilitesADXN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

ADXN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 119.91%, which is quite impressive.
ADXN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -76.09%.
The Revenue for ADXN have been decreasing by -24.47% on average. This is quite bad
EPS 1Y (TTM)119.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.28%
Revenue 1Y (TTM)-76.09%
Revenue growth 3Y-24.84%
Revenue growth 5Y-24.47%
Sales Q2Q%-82.26%

3.2 Future

ADXN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.71% yearly.
ADXN is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y103.68%
EPS Next 2Y24.85%
EPS Next 3Y19.49%
EPS Next 5Y14.71%
Revenue Next Year-73.55%
Revenue Next 2Y-54.41%
Revenue Next 3Y-40.77%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ADXN Yearly Revenue VS EstimatesADXN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
ADXN Yearly EPS VS EstimatesADXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 0 -10 -20 -30 -40 -50

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 1.32 indicates a rather cheap valuation of ADXN.
ADXN's Price/Earnings ratio is rather cheap when compared to the industry. ADXN is cheaper than 99.49% of the companies in the same industry.
ADXN's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.64.
ADXN is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 1.32
Fwd PE N/A
ADXN Price Earnings VS Forward Price EarningsADXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADXN Per share dataADXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ADXN's earnings are expected to grow with 19.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y24.85%
EPS Next 3Y19.49%

More info and screens

0

5. Dividend

5.1 Amount

ADXN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADDEX THERAPEUTICS LTD

NASDAQ:ADXN (4/23/2025, 8:00:00 PM)

7.6

-0.04 (-0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-24 2025-03-24/amc
Earnings (Next)05-19 2025-05-19
Inst Owners4.05%
Inst Owner Change51.06%
Ins Owners10.84%
Ins Owner ChangeN/A
Market Cap8.12M
Analysts38
Price Target7.61 (0.13%)
Short Float %0.34%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.31%
PT rev (3m)-6.95%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)107.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)133.37%
Valuation
Industry RankSector Rank
PE 1.32
Fwd PE N/A
P/S 11.27
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)5.75
EY75.66%
EPS(NY)-6.85
Fwd EYN/A
FCF(TTM)-6.8
FCFYN/A
OCF(TTM)-6.8
OCFYN/A
SpS0.67
BVpS12.59
TBVpS12.57
PEG (NY)0.01
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 44.42%
ROE 48.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 912.34%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.79%
Cap/Sales 0.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.59
Quick Ratio 4.59
Altman-Z -34.39
F-Score6
WACC5.15%
ROIC/WACCN/A
Cap/Depr(3y)3.83%
Cap/Depr(5y)7.14%
Cap/Sales(3y)0.49%
Cap/Sales(5y)0.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)119.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.28%
EPS Next Y103.68%
EPS Next 2Y24.85%
EPS Next 3Y19.49%
EPS Next 5Y14.71%
Revenue 1Y (TTM)-76.09%
Revenue growth 3Y-24.84%
Revenue growth 5Y-24.47%
Sales Q2Q%-82.26%
Revenue Next Year-73.55%
Revenue Next 2Y-54.41%
Revenue Next 3Y-40.77%
Revenue Next 5Y-14.87%
EBIT growth 1Y65.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.21%
EBIT Next 3Y19.77%
EBIT Next 5Y11.87%
FCF growth 1Y63.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.38%
OCF growth 3YN/A
OCF growth 5YN/A